急性脑梗死静脉溶栓治疗的难点与对策

Discussion for the Problems in Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in Acute Cerebral Infarction

本文指出按照国际指南以重组组织型纤溶酶原激活剂(r-tPA)进行规范静脉溶栓治疗急性脑梗死的重要性;提出了临床实践中常见的5方面问题:接受溶栓治疗的急性脑梗死患者较少、r-tPA的价格限制了临床应用、中国人r-tPA用量尚待摸索、溶栓疗效不理想以及中医药参与溶栓治疗有限,并对每一问题提出应对措施。对中医药干预超早期脑梗死溶栓治疗提出自己的想法。

This paper points out the importance of intravenous thrombolysis with recombinant tissue plasminogen activator （r-tPA） according to the international guidelines in acute ischemic stroke. Some practical problems, such as the lower rate of thrombolysis for ischemic stroke, the price of r-tPA being too expensive to clinical using, the dosage of r-tPA in Chinese being not clear, the curative effect being not so good, and traditional Chinese medicine （TCM） applied in intravenous thrombolysis, and so on, should be further discussed.